News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Lannett Company, Inc. (LCI) Comments On Utilization Of Digoxin


8/20/2014 10:18:08 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

PHILADELPHIA--(BUSINESS WIRE)--Lannett Company, Inc. (NYSE: LCI) today commented on the utilization of Digoxin, following a recently published abstract in the Journal of the American College of Cardiology (JACC), which suggested a potential increased risk of mortality in patients with newly diagnosed atrial fibrillation. The abstract was based on data of the TREAT-AF (The Retrospective Evaluation and Assessment of Therapies in AF) study from the U.S. Department of Veterans Affairs (VA) healthcare system.

“Digoxin has long been an important treatment option for cardiovascular disease,” said Arthur Bedrosian, president and chief executive officer of Lannett. “As with most medications, we believe medical care providers will continue to prescribe Digoxin unless a more effective alternative medication is available.”

Hey, check out all the research scientist jobs. Post your resume today!

Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES